Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Dyskinesias

• Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
• Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
• Study Evaluating the Safety and Tolerability of RCT1100 in Healthy Subjects
• Open-Label Extension Study of ASTORIA
• A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease
• Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced Dyskinesia
• A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects
• Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
• Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia
• Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
• Reduction of Demoralization After Treatment of TD With Valbenazine
• Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia
• Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype
• Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
• Pimavanserin Treatment in TS
• A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia
• Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components
• Double Randomized and Placebo Controlled Trail of Tianqi Pingchan Granule to Prevent Levodopa-Induced Dyskinesia
• Clinical Study on Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine
• AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia
• Safinamide for Levodopa-induced Dyskinesia (PD-LID)
• A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia
• A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease
• Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia
• A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
• The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine
• A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia
• Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
• Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia
• Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)
• Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia
• Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia
• Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia
• A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
• Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
• Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease
• Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia
• Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia
• Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia
• A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients
• Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
• Addressing Involuntary Movements in Tardive Dyskinesia
• Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
• A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
• Open-Label Safety Study of ADS-5102 in PD Patients With LID
• Reducing Involuntary Movements in Participants With Tardive Dyskinesia
• Aim to Reduce Movements in Tardive Dyskinesia
• Trial of Laparoscopic Cholecystectomy vs. Non-operative Treatment for Gallbladder Dyskinesia
• Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease
• Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.
• Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID
• ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
• A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia
• Famotidine for Levodopa-induced Dyskinesia in PD
• Pyridoxal Kinase Activity in Tardive Dyskinesia
• Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
• Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
• NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
• Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids
• Xenazine in Late Dyskinetic Syndrome With Neuroleptics
• Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease
• Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
• Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
• Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
• Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
• Melatonin Treatment for Tardive Dyskinesia in Schizophrenia
• Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
• ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease
• Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia
• Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
• A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety, Tolerability and Efficacy of E2007 in Parkinson's Disease Patients With "Wearing Off" Motor Fluctuations and "On" Period Dyskinesias
• Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects
• Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia
• Validation of Dyskinesia Rating Scales
• Natural History of Levodopa-Induced Dyskinesia (LID)
• Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
• Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy
• Tardive Dyskinesia and Cognitive Function
• Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
• A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.
• Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics
• Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients
• Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)
• Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia
• Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)
• Extract of Ginkgo Biloba and Tardive Dyskinesia
• Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia
• Safety, Tolerability, PK and PD Study of Neu-120 in the Treatment of Levodopa-induced Dyskinesia
• Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa
• The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial
• Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)
• The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations
• Dyskinesia in Parkinson's Disease (Study P04501)
• Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia
• Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's
• Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects
• Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia
• Sarizotan in the Treatment of Neuroleptic-induced Tardive Dyskinesia
• Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease
• Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's Disease
• Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease
• Levetiracetam Treatment of Tardive Dyskinesia
• Movement Disorders Caused by Antipsychotic Drugs in Older Patients
• Piracetam for Treatment Tardive Dyskinesia
• Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia
• Treatment of Tardive Dyskinesia With Galantamine
• Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias
• Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
• Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
• Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
• ACP-103 to Treat Parkinson's Disease
• Levetiracetam Treatment of L-dopa Induced Dyskinesias
• Effects of Talampanel on Patients With Advanced Parkinson's Disease
• Study of LY300164 for the Treatment of Parkinson's Disease